Table 6. Univariate and multivariate analysis of the factors affecting PFS.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | ||
| Age (year) | 0.112 | ||||
| Gender (male vs. female) | 0.927 | ||||
| ASA score (1–2 vs. 3–4) | 0.872 | ||||
| Comorbidity (reference, no) | 0.757 | ||||
| 1 | |||||
| ≥2 | |||||
| NCT regimens (SOX/XELOX vs. paclitaxel plus SOX/XELOX) | 0.295 | ||||
| Completion of NCT (yes) | 0.643 | ||||
| Time to surgery (reference, ≤4 weeks) | 0.044 | 1 | Reference | ||
| 5–6 weeks | 1.176 | 0.742–1.865 | 0.490 | ||
| >6 weeks | 0.637 | 0.345–1.176 | 0.149 | ||
| Gastrectomy (subtotal vs. total) | <0.001 | 1.870 | 1.205–2.902 | 0.005 | |
| Additional organs resection | 0.478 | ||||
| Differentiation (well/moderate vs. poor/undifferentiated) | <0.001 | 2.787 | 1.473–5.272 | 0.002 | |
| HPR (1–3 vs. 4–5) | 0.049 | 0.827 | 0.529–1.291 | 0.403 | |
| pT stage (pT0–2 vs. pT3–4) | <0.001 | 1.369 | 0.751–2.495 | 0.305 | |
| pN stage (pN0 vs. pN+) | <0.001 | 2.051 | 1.187–3.545 | 0.010 | |
| Resection margin (R0 vs. R1) | <0.001 | 2.188 | 1.068–4.482 | 0.032 | |
| Adjuvant chemotherapy (none) | 0.201 | ||||
| Incomplete | |||||
| Complete | |||||
PFS, progression-free survival; HR, hazards ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; NCT, neoadjuvant chemotherapy; SOX, oxaliplatin + S-1; XELOX, oxaliplatin + capecitabine; HPR, histopathological response.